Statins and Their Influence on Major Depressive Disorder

Major depressive disorder (MDD) is a leading cause of global disability, often resistant to standard monoaminergic therapies. Statins, or HMG-CoA reductase inhibitors, are established treatments for dyslipidaemia and cardiovascular risk reduction, but they also possess anti-inflammatory, endothelial-modulating and neuroprotective properties. Epidemiological studies have linked statin use to a lower incidence of depressive symptoms and to improved adherence when statins are combined with conventional antidepressants. Mechanistic research points to effects on neuroinflammation, serotonergic neurotransmission, hypothalamic–pituitary–adrenal axis regulation and neuroplasticity. Nevertheless, the relationship between lipid metabolism and mood is complex, with some studies suggesting neutral or variable outcomes on depressive scores. Given their safety profile, wide availability and affordability, statins represent attractive candidates for adjunctive treatment in MDD, particularly for patients with treatment-resistant depression or comorbid cardiometabolic disorders.

Research from Nature Portfolio

Recent investigations in animal models have illuminated statins’ central mechanisms. In a foundational rodent study modelling diet-induced emotional disturbances, simvastatin administration ameliorated anxiety- and depression-like behaviours in mice fed a high-fat diet. Behavioural assays demonstrated reduced immobility and increased sucrose preference, while metabolomic analyses revealed restoration of disrupted endocannabinoid signalling pathways. This work underscores the significance of lipid-derived neuromodulators in mood regulation and provides a mechanistic basis for translational efforts in human MDD.

Statins and Their Influence on Major Depressive Disorder publication trend

The graph below shows the total number of articles in statins and their influence on major depressive disorder across all publications each year (not limited to Nature Index journals).

Technical terms

HMG-CoA reductase inhibitor: A class of drugs that block the rate-limiting enzyme in cholesterol synthesis.

Neuroinflammation: Immune-related processes within the central nervous system that can alter neuronal signalling and affective states.

Endocannabinoid system: A lipid-based neuromodulatory network involved in regulating stress, mood and reward pathways.

Randomised controlled trial: An experimental study design in which participants are randomly assigned to intervention or control groups to evaluate treatment efficacy.

References

1. The pharmacological bases for repurposing statins in depression: a review of mechanistic studies. Translational Psychiatry (2023).
2. Statin use and risk of depression: a Swedish national cohort study. BMC Psychiatry (2014).
3. Simvastatin and Bezafibrate ameliorate Emotional disorder Induced by High fat diet in C57BL/6 mice. Scientific Reports (2017).
4. Real-world outcomes of concomitant antidepressant and statin use in primary care patients with depression: a population-based cohort study. BMC Medicine (2023).
5. Mortality and adverse events associated with statin use in primary care patients with depression: a real-world, population-based cohort study. BMJ Mental Health (2024).
6. Effect of a high dose atorvastatin as added-on therapy on symptoms and serum AMPK/NLRP3 inflammasome and IL-6/STAT3 axes in patients with major depressive disorder: randomized controlled clinical study. Frontiers in Pharmacology (2024).